In March 2019 I had the opportunity to interview Jennifer Newman, global project leader, regulatory affairs/clinical operations for Celldex Therapeutics. Newman was once part of the largest implementation of risk-based monitoring (RBM) and was able to share insights from her experience. Specifically, she was able to discuss the benefits and challenges of RBM and what companies should be prepared for when adopting the technology. The videos below feature some of the highlights of that discussion. You can also view the entire discussion here.